Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and Europe. It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The company also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. Inspire Medical Systems, Inc. was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
IPO Year: 2018
Exchange: NYSE
Website: inspiresleep.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2024 | $220.00 → $255.00 | Neutral → Buy | BofA Securities |
| 5/8/2024 | $265.00 → $225.00 | Buy → Neutral | BofA Securities |
| 4/19/2024 | $285.00 | Outperform | RBC Capital Mkts |
| 3/19/2024 | $250.00 | Overweight | Morgan Stanley |
| 2/6/2024 | $278.00 | Overweight | KeyBanc Capital Markets |
| 1/19/2024 | $245.00 | Buy | Jefferies |
| 1/2/2024 | $210.00 | Buy → Hold | Stifel |
| 12/13/2023 | $245.00 → $187.00 | Overweight → Equal Weight | Wells Fargo |
| 7/19/2023 | $371.00 | Outperform | Robert W. Baird |
| 4/14/2023 | $300.00 | Buy | Mizuho |
8-K - Inspire Medical Systems, Inc. (0001609550) (Filer)
10-Q - Inspire Medical Systems, Inc. (0001609550) (Filer)
8-K - Inspire Medical Systems, Inc. (0001609550) (Filer)
144 - Inspire Medical Systems, Inc. (0001609550) (Subject)
10-Q - Inspire Medical Systems, Inc. (0001609550) (Filer)
8-K - Inspire Medical Systems, Inc. (0001609550) (Filer)
8-K - Inspire Medical Systems, Inc. (0001609550) (Filer)
8-K - Inspire Medical Systems, Inc. (0001609550) (Filer)
144 - Inspire Medical Systems, Inc. (0001609550) (Subject)
8-K - Inspire Medical Systems, Inc. (0001609550) (Filer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured
"Inspire has a long history of compliance to the European Union's (EU) quality system and CE mark requirements, with uninterrupted CE mark approval since 2010," said Tim Herbert, Chairman and President of Inspire. "The Inspire team has worked diligently with our notified body in Europe to complete the review process, which included obtaining temporary approval through derogation authorization to continue to deliver Inspire product in several countries." "In 2017 the European Parliament enacted a new regulatory framework (i.e., EU MDR 2017/745) for the certification of medical devices in the EU. As a result, the entire medical device industry must repeat the process for both design and quali
Ratings for Inspire Medical Systems (NYSE:INSP) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 2 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 1 0 0 2M Ago 0 0 1 0 0 3M Ago 0 2 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $220.33, a high estimate of $285.00, and a low estimate of $170.00. Highlighting a 9.
Truist Securities analyst Richard Newitter maintains Inspire Medical Systems (NYSE:INSP) with a Buy and lowers the price target from $280 to $217.
Morgan Stanley analyst Kallum Titchmarsh maintains Inspire Medical Systems (NYSE:INSP) with a Overweight and lowers the price target from $250 to $210.
The FDA has labeled a recall of Inspire Medical Systems, Inc.’s (NYSE:INSP) nerve-stimulating implant for obstructive sleep apnea as Class I, the most serious kind. Inspire initiated a recall of its IV Implantable Pulse Generator (IPG) on June 17. The recall extends to 32 devices of the Model 3028 IPG. Inspire Medical Systems is recalling Inspire IV Implantable Pulse Generator (IPG) Model 3028 due to a manufacturing defect. The defect can cause system malfunctions after implantation, leading to electrical leakage in the sensing circuit. As a result, patients may need revision surgery to replace the IPG and restore therapy. The use of the affected product may cause serious advers
- Reuters
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Monday. Shares of ResMed Inc. (NYSE:RMD) fell sharply during Monday's session following sleep apnea data from Lilly. Citigroup analyst Mathieu Chevrier downgraded ResMed from Buy to Neutral. ResMed shares dipped 10.4% to $184.35 on Monday. Here are some other big stocks recording gains in today’s session. Molecular Partners AG (NASDAQ:MOLN) shares dipped 22.6% to $7.43. Cryoport, Inc. (NASDAQ:CYRX) fell 19.9% to $7.77. Cryoport announced a strategic partnership with Minaris Regenerative Medicine for cell and gene therapies advancement. BridgeBio Pharma, Inc. (NASDAQ:BBIO) dipped 19.2% to $22.1
In the latest quarter, 5 analysts provided ratings for Inspire Medical Systems (NYSE:INSP), showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 2 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 1 0 0 2M Ago 0 1 0 0 0 3M Ago 1 1 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Inspire Medical Systems, presenting an average target of $229.0, a high estimate of $285.00, and a low estimate of $170.00. A nega
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
BofA Securities upgraded Inspire Medical Systems from Neutral to Buy and set a new price target of $255.00 from $220.00 previously
BofA Securities downgraded Inspire Medical Systems from Buy to Neutral and set a new price target of $225.00 from $265.00 previously
RBC Capital Mkts initiated coverage of Inspire Medical Systems with a rating of Outperform and set a new price target of $285.00
Morgan Stanley initiated coverage of Inspire Medical Systems with a rating of Overweight and set a new price target of $250.00
KeyBanc Capital Markets resumed coverage of Inspire Medical Systems with a rating of Overweight and set a new price target of $278.00
Jefferies initiated coverage of Inspire Medical Systems with a rating of Buy and set a new price target of $245.00
Stifel downgraded Inspire Medical Systems from Buy to Hold and set a new price target of $210.00
Wells Fargo downgraded Inspire Medical Systems from Overweight to Equal Weight and set a new price target of $187.00 from $245.00 previously
Robert W. Baird initiated coverage of Inspire Medical Systems with a rating of Outperform and set a new price target of $371.00
Mizuho initiated coverage of Inspire Medical Systems with a rating of Buy and set a new price target of $300.00
SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)
SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)
SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)
SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)
SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)
SC 13G - Inspire Medical Systems, Inc. (0001609550) (Subject)
SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)
SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)
SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)
SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended September 30, 2024. Recent Business Highlights Generated revenue of $203.2 million in the third quarter of 2024, a 33% increase over the same quarter last yearAchieved gross margin of 84.1% in the third quarter of 2024Generated $14.3 million in operating income and earnings per share of $0.60 in the third quarter of 2024Generated cash flow from operations of
MINNEAPOLIS, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the third quarter 2024 after the close of trading on Monday, November 4. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q3 2024 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the followi
MINNEAPOLIS, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended June 30, 2024. Recent Business Highlights Generated revenue of $195.9 million in the second quarter of 2024, a 30% increase over the same quarter last yearAchieved gross margin of 84.8% in the second quarter of 2024Generated $5.1 million in operating income and earnings per share of $0.32 in the second quarter of 2024Activated 81 new U.S. centers in
MINNEAPOLIS, July 29, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced certain preliminary, unaudited results for the quarter ended June 30, 2024, and updated full year 2024 revenue outlook. The company plans to report its complete results and host its earnings conference call for the second quarter of 2024 on August 6, 2024. Preliminary, Unaudited Second Quarter Revenue Revenue for the second quarter is anticipated to be $195.9 million, a 30% increase over the same quarter of 2023 U.S.
MINNEAPOLIS, July 02, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the second quarter 2024 after the close of trading on Tuesday, August 6. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q2 2024 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the followi
Inspire Reports Year-over-YearRevenue Growth of 28% in the First Quarter and Expects Profitability for the Full Year 2024 MINNEAPOLIS, May 07, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2024. Recent Business Highlights Generated revenue of $164.0 million in the first quarter of 2024, a 28% increase over the same quarter last yearAchieved gross margin of 84.9% in the first quarter of 2024Activated 66 new U.S.
MINNEAPOLIS, April 02, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the first quarter 2024 after the close of trading on Tuesday, May 7. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q1 2024 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the following
Inspire Reports First Quarter with Operating Income and Year-over-Year Revenue Growth of 40% in the Fourth Quarter MINNEAPOLIS, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter and year ended December 31, 2023. Recent Business Highlights and Full Year 2024 Guidance Generated revenue of $192.5 million in the fourth quarter of 2023, a 40% increase over the same quarter last year, and revenue of $624.8 million in full year 2023, a 53% increa
MINNEAPOLIS, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the fourth quarter and fiscal 2023 after the close of trading on Tuesday, February 6. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q4 2023 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please us
MINNEAPOLIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2023, and provided its initial full year 2024 guidance. Preliminary, Unaudited Fourth Quarter and Full Year 2023 Revenue and Recent Business Highlights Revenue for the fourth quarter of 2023 is anticipated to be in the range of $192.3 million to $192.5 million, an approximately 40% increase over the same quarter of 202
MINNEAPOLIS, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024. Inspire is scheduled to present at 12:00 p.m. Eastern Time. The presentation will be accessible via a live webcast here. Webcast replays of the presentations will be available for two weeks following the presentations in the Event Archive section of Inspire's Investor website at https://
MINNEAPOLIS, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Inspire is scheduled to present at 7:30 a.m. Eastern Time. The presentation will be accessible via a live webcast here. Webcast replays of the presentations will be available for two weeks following the presentations in the Event Archive section of Inspire's Investor website at https://investors.i
MINNEAPOLIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) ("Inspire," or the "Company"), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced that it entered into an accelerated share repurchase ("ASR") transaction under an agreement with Goldman Sachs & Co. LLC, to repurchase an aggregate of $75.0 million of shares of the Company's common stock, par value $0.001 per share. The ASR transaction is being completed pursuant to a previously announced $150.0 million share repurchase program authorized by the Company's Board of Directors.
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended September 30, 2024. Recent Business Highlights Generated revenue of $203.2 million in the third quarter of 2024, a 33% increase over the same quarter last yearAchieved gross margin of 84.1% in the third quarter of 2024Generated $14.3 million in operating income and earnings per share of $0.60 in the third quarter of 2024Generated cash flow from operations of
MINNEAPOLIS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the UBS Global Healthcare Conference on Wednesday, November 13, 2024. Inspire is scheduled to present at 11:00 a.m. Eastern Time. The presentation will be accessible via a live webcast here. Webcast replays of the presentations will be available for two weeks following the presentations in the Event Archive section of Inspire's Investor website at https://investors.inspir
MINNEAPOLIS, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the third quarter 2024 after the close of trading on Monday, November 4. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q3 2024 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the followi
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
MINNEAPOLIS, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Morgan Stanley 22nd Annual Global Healthcare Conference and the Wells Fargo 2024 Healthcare Conference on Wednesday, September 4, 2024. Inspire is scheduled to present at the Morgan Stanley conference at 7:00 a.m. Eastern Time. The presentation will be accessible via a live webcast here. Inspire is scheduled to present at the Wells Fargo conference at 3:00 p.m. Easter
MINNEAPOLIS, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended June 30, 2024. Recent Business Highlights Generated revenue of $195.9 million in the second quarter of 2024, a 30% increase over the same quarter last yearAchieved gross margin of 84.8% in the second quarter of 2024Generated $5.1 million in operating income and earnings per share of $0.32 in the second quarter of 2024Activated 81 new U.S. centers in
MINNEAPOLIS, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that its Board of Directors has authorized the repurchase of up to $150.0 million of the company's outstanding shares of common stock. "I am pleased to announce our intention to purchase up to $150.0 million of Inspire common stock - the first share repurchase by Inspire in its history," said Tim Herbert, Chairman and Chief Executive Officer. "During the second quarter, we made significant p
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
MINNEAPOLIS, July 22, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today the addition of Melissa J. Mann as Chief People Officer, effective July 22, 2024. "We are very excited to welcome Melissa to the Inspire team," said Tim Herbert, Chairman and CEO of Inspire. "In this role, Melissa will be able to leverage her vast experience in human capital management as we continue to grow and scale our organization. Melissa is replacing Steven L. Jandrich, Vice President, Human Resources, who
MINNEAPOLIS, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the retirement of Marilyn Carlson Nelson as Chair of its Board of Directors and the appointment of Chief Executive Officer Timothy P. Herbert to the additional role of Board Chair, to be effective at the conclusion of the Company's Annual Meeting of Stockholders scheduled to occur on May 2, 2024. "Marilyn has had a profound impact on our business and our employees through her many years on the board," said
MINNEAPOLIS, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the retirement of Jerry C. Griffin, M.D., from its Board of Directors, to be effective at the conclusion of the Company's Annual Meeting of Stockholders scheduled to occur on May 2, 2024. "After sixteen years of service, we announce the retirement of Dr. Griffin from our Board of Directors. His contributions to our Board and organization are innumerable and we are grateful for the dedication and direction h
MINNEAPOLIS, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the appointment of Myriam J. Curet, M.D., as an independent Director to its Board, effective December 21, 2023. "We are excited to add Dr. Curet, a practicing, board-certified minimally invasive general surgeon with extensive business and executive leadership experience in the medical device industry to our Board of Directors," said Tim Herbert, President and Chief Executive Officer of Inspire Medical Syste
PHILADELPHIA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- LifeLens Technologies, Inc. (LifeLens), a medical technology company that provides real-time physiological monitoring, today announced the appointment of three industry veterans to the following positions on its executive leadership team and Board of Directors: Daniel J. Sullivan, Chairman of the Board of LifeLens, as Chief Executive OfficerBrent A. Moen as Chief Financial OfficerRichard J. Buchholz as a member of the Board of Directors "With LifeLens, we have a significant opportunity to disrupt healthcare and make a meaningful impact on patients and healthcare professionals, and we are thrilled to have Brent and Rick join the LifeLens tea
MINNEAPOLIS, July 24, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the appointment of Carlton Weatherby as Chief Strategy Officer, effective July 24, 2023. "We are very excited to welcome Carlton to the Inspire team," said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems. "Carlton's vast experience in leadership roles across medtech, as well as his strategic vision, will be very valuable to us as we continue to grow and scale as an organization
NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors. "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through se
MINNEAPOLIS, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced the appointment of Ezgi Yagci as Vice President of Investor Relations, effective August 15, 2022. "The team is very excited to welcome Ezgi and her vast experience in the medical technology sector to Inspire," said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems. "She will have a positive impact on our expanding investor relations program and play a key role in contributing to the ov
MINNEAPOLIS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced the appointments of Cynthia Burks and Charisse Sparks, M.D., as independent directors to its Board, effective July 28, 2022. Cynthia Burks is the former Chief Human Resources Officer for Genentech, Inc., a member of the Roche Group. In this role, Ms. Burks led the company's efforts to attract, develop and retain employees at Genentech, which has over 13,500 employees. An innovative leader, she brings strong ana